Prevention of heart failure in the elderly: when, where and how to begin?

被引:10
|
作者
Jugdutt, Bodh I. [1 ]
机构
[1] Univ Alberta & Hosp, Div Cardiol, Dept Med, Walter MacKenzie Hlth Sci Ctr 2C2, Edmonton, AB T6G 2R7, Canada
基金
加拿大健康研究院;
关键词
Aging; Heart failure; Markers; Telomere length; Prevention strategies; CARDIOVASCULAR-DISEASE ENTERPRISES; ATHEROSCLEROTIC VASCULAR-DISEASE; CORONARY-ARTERY CALCIFICATION; HEALTH-CARE PROFESSIONALS; LEUKOCYTE TELOMERE LENGTH; CARDIAC TROPONIN-T; ATRIAL-FIBRILLATION; RISK-FACTORS; MYOCARDIAL-INFARCTION; NATRIURETIC PEPTIDE;
D O I
10.1007/s10741-012-9299-x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Significant growth in the elderly population (age a parts per thousand yen 65 years) with heart failure (HF) has taken place in developed countries and is occurring in most developing countries. Projections from population studies in the United States, Europe and other developed countries suggest that this trend will very likely continue and tax healthcare systems worldwide. Prevention of HF in the elderly should be a healthcare priority. Preventive strategies are urgently needed to combat the rising burden of HF and related complications in elderly men and women of tomorrow. The strategies should address the aging continuum and the cumulative impact of lifelong exposure to cardiovascular (CV) risk factors and consider the associated pathobiology and pathophysiology of aging for optimal impact. Besides implementation of conventional primary and secondary prevention measures in young and older adults, more emphasis should be placed on education about the role of exposure to adverse CV risk factors from early childhood in the march to HF. More research is also needed to identify optimal HF therapies for different aging subgroups ranging from young adults to the elderly and very old based on understanding of pathobiology and pathophysiology.
引用
收藏
页码:531 / 544
页数:14
相关论文
共 50 条
  • [1] Prevention of heart failure in the elderly: when, where and how to begin?
    Bodh I. Jugdutt
    Heart Failure Reviews, 2012, 17 : 531 - 544
  • [2] When should heart disease prevention begin?
    Gaziano, JM
    NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (23): : 1690 - 1692
  • [4] Heart failure in an elderly man: where is that coronary?
    Sang, Charlie J.
    Clarkson, Stephen A.
    Jackson, Elizabeth A.
    Al Solaiman, Firas
    Cribbs, Marc G.
    CARDIOLOGY IN THE YOUNG, 2021, 31 (06) : 1030 - 1033
  • [5] Treating iron deficiency in patients with heart failure: what, why, when, how, where and who
    Graham, Fraser J.
    Guha, Kaushik
    Cleland, John G.
    Kalra, Paul R.
    HEART, 2024,
  • [6] WHERE DO ELDERLY PATIENTS WITH HEART FAILURE DIE?
    French, M.
    Owles, H.
    Baxter, A. J.
    AGE AND AGEING, 2011, 40 : II23 - II23
  • [7] When, how and where should we "coach" patients with heart failure: The COACH results in perspective
    Harsma, Tiny
    van Veldhuisen, Dirk J.
    EUROPEAN JOURNAL OF HEART FAILURE, 2008, 10 (04) : 331 - 333
  • [8] β-blockers for heart failure:: why, which, when, and where
    Cleland, JGF
    MEDICAL CLINICS OF NORTH AMERICA, 2003, 87 (02) : 339 - +
  • [9] Heart failure in the elderly: How risky is it to be discharged?
    Nieminen, Markku S.
    Harjola, Veli-Pekka
    EUROPEAN JOURNAL OF HEART FAILURE, 2008, 10 (03) : 222 - 223
  • [10] Pacing in heart failure: how many leads and where?
    Barold, S. Serge
    Herwerg, Bengt
    HEART, 2008, 94 (01) : 10 - 12